



A0787

This month's MOTM is Niraparib Tosylate. Developed by Tesaro, Niraparib is an orally active and potent poly (ADP-ribose) polymerase (or PARP) inhibitor, which is now a phase III candidate for the treatment of ovarian and breast cancer.

LCC's process chemistry team have developed a highly efficient synthetic route that provides access to both enantiomers of Niraparib in >99% ee and has already been piloted on kilogram scale. As a result, LCC can also provide the intermediates to aid analogue synthesis.

LCC will continue to apply its expertise in catalysis and chiral chemistry to produce building blocks, key intermediates and API. If you are interested in similar products and feel you could benefit from our services, I'd be delighted to talk with you.

Regards,

Dr Paul Colbon

CEO & Co-Founder

Office: +44(0)151 794 2936 | Mobile: +44(0)7415946636

Email: paul.colbon@liverpoolchirochem.co.uk



BUILDING BLOCKS



SCREENING
LIBRARIES



CHEMISTRY
SERVICES



MOLFINDER

